These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 109501)

  • 81. Protective efficacy of recombinant exotoxin A--flagellin fusion protein against Pseudomonas aeruginosa infection.
    Farajnia S; Peerayeh SN; Tanomand A; Majidi J; Goudarzi G; Naghili B; Rahbarnia L
    Can J Microbiol; 2015 Jan; 61(1):60-4. PubMed ID: 25496361
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Pseudomonas vaccine. 3. Evaluation of a polyvalent vaccine.
    De Fajardo CL; Laborde HF
    J Bacteriol; 1968 May; 95(5):1968-9. PubMed ID: 4967780
    [No Abstract]   [Full Text] [Related]  

  • 83. Production and characterization of a human hyperimmune intravenous immunoglobulin against Pseudomonas aeruginosa and Klebsiella species.
    Cryz SJ; Fürer E; Sadoff JC; Fredeking T; Que JU; Cross AS
    J Infect Dis; 1991 May; 163(5):1055-61. PubMed ID: 1902245
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Treatment of experimental burn wound sepsis by postburn immunization with polyvalent Pseudomonas antigen.
    Nance FC; Hines JL; Fulton RE; Bornside GH
    Surgery; 1970 Jul; 68(1):248-53. PubMed ID: 10483476
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Characterisation of mouse monoclonal antibodies produced by immunisation with a single serotype component of a polyvalent Pseudomonas aeruginosa vaccine.
    Barclay GR; Yap PL; McClelland DB; Jones RJ; Roe EA; McCann MC; Micklem LR; James K
    J Med Microbiol; 1986 Feb; 21(1):87-90. PubMed ID: 3081727
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Protection by vaccination against Pseudomonas infection after thermal injury.
    Markley K; Smallman E
    J Bacteriol; 1968 Oct; 96(4):867-74. PubMed ID: 4971892
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The first clinical trial of immuno's experimental Pseudomonas aeruginosa flagellar vaccines.
    Crowe BA; Enzersberger O; Schober-Bendixen S; Mitterer A; Mundt W; Livey I; Pabst H; Kaeser R; Eibl M; Eibl J
    Antibiot Chemother (1971); 1991; 44():143-56. PubMed ID: 1801633
    [No Abstract]   [Full Text] [Related]  

  • 88. Comparison of two immunization schedules for a Pseudomonas aeruginosa outer membrane proteins vaccine in burn patients.
    Kim DK; Kim JJ; Kim JH; Woo YM; Kim S; Yoon DW; Choi CS; Kim I; Park WJ; Lee N; Jung SB; Ahn BY; Nam SW; Yoon SM; Choi WJ
    Vaccine; 2000 Dec; 19(9-10):1274-83. PubMed ID: 11137267
    [TBL] [Abstract][Full Text] [Related]  

  • 89. [The immunogenic properties of the liposomal form of Pseudomonas aeruginosa anatoxin in burned and irradiated mice].
    Minukhin VV; Brodinova NS; Tsyganenko AIa; Tkachenko VL; Ivanova NN; Vasil'chenko VN
    Zh Mikrobiol Epidemiol Immunobiol; 1993; (6):69-71. PubMed ID: 8079576
    [No Abstract]   [Full Text] [Related]  

  • 90. Immunity against Pseudomonas aeruginosa adoptively transferred to bone marrow transplant recipients.
    Gottlieb DJ; Cryz SJ; Furer E; Que JU; Prentice HG; Duncombe AS; Brenner MK
    Blood; 1990 Dec; 76(12):2470-5. PubMed ID: 2124933
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Current status of Pseudomonas aeruginosa vaccine.
    Michelim L; Medeiros GS; Zavascki AP
    Curr Pharm Biotechnol; 2013; 14(11):951-9. PubMed ID: 24372247
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Effects of dietary arginine supplementation on antibody production and antioxidant enzyme activity in burned mice.
    Shang HF; Tsai HJ; Chiu WC; Yeh SL
    Burns; 2003 Feb; 29(1):43-8. PubMed ID: 12543044
    [TBL] [Abstract][Full Text] [Related]  

  • 93. [Experimental vaccinal prophylaxis of Pseudomonas aeruginosa burn sepsis].
    Bandman OA; Stanislavskiĭ ES; Kholodkova EV; Ivanova TV; Salov VF
    Zh Mikrobiol Epidemiol Immunobiol; 1989 Jul; (7):59-62. PubMed ID: 2510430
    [TBL] [Abstract][Full Text] [Related]  

  • 94. [Effectiveness of a polyvalent corpuscular Pseudomonas aeruginosa vaccine, antibiotics and their combinations in experimental chronic Pseudomonas aeruginosa infection].
    Vetkova LG; Antsiferova NG; Radkevich SA; Moroz AF
    Zh Mikrobiol Epidemiol Immunobiol; 1985 Mar; (3):51-6. PubMed ID: 3922187
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Enzyme-linked immunosorbent assay antibody responses to a temperature-sensitive mutant of Pseudomonas aeruginosa.
    Sordelli DO; Rojas RA; Cerquetti MC; Hooke AM; Degnan PJ; Bellanti JA
    Infect Immun; 1985 Oct; 50(1):324-7. PubMed ID: 3930404
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Role of nonagglutinating antibody in the protracted immunity of vaccinated mice to Pseudomonas aeruginosa infection.
    Moody MR; Kessel RW; Young VM; Fiset P
    Infect Immun; 1978 Sep; 21(3):905-13. PubMed ID: 101467
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Experimental studies on the protective efficacy of a Pseudomonas aeruginosa vaccine.
    Stanislavsky ES; Edvabnaya LS; Bandman OA; Boolk VF; Zhvanetskaya MI; Vargina AK
    Vaccine; 1989 Dec; 7(6):562-6. PubMed ID: 2514518
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Anti-Pseudomonas aeruginosa activity of an intravenous human IgG preparation in burned mice.
    Collins MS; Roby RE
    J Trauma; 1983 Jun; 23(6):530-4. PubMed ID: 6408266
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Protective immunization against chronic Pseudomonas aeruginosa pulmonary infection in rats.
    Klinger JD; Cash HA; Wood RE; Miler JJ
    Infect Immun; 1983 Mar; 39(3):1377-84. PubMed ID: 6404823
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Evaluation of protein A and protein G as indicator system in an ELISA for detecting antibodies in mink to Pseudomonas aeruginosa.
    Rivera E; Jackert-Jernberger M; Mejerland T; Karlsson KA
    Vet Microbiol; 1994 Dec; 42(4):265-71. PubMed ID: 9133051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.